‘No deviations from the provisions of TRIPS’
Dr P Murali, President, ABLE & CEO, Evolva Biotech
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
’Need innovation policy wider than a Patent Act’
Leena Menghaney, India Campaign Manager Access Campaign Médecins Sans Frontières
’Law has a strong element of public policy’
Prof Raghavendra Lal Saha headed the Patent Facilitating Centre, TIFAC for many years starting from its inception and has been a…
’India yet to benefit from the new patent system’
Reji K Joseph is a consultant with Research and Information System for Developing Countries(RIS), a think tank with Government of…
’Failed to promote, nurture innovation’
Anay Shukla, Member, Pharma & Life Science team, Nishith Desai Associates
’Discourages the ’art of ever-greening”
Dr Gopakumar G Nair was the Dean of Institute of Intellectual Property Studies (IIPS) at Hyderabad, India. Presently he heads his…
’Strike a balance between public & private interest’
Raghu Cidambi was legal affairs advisor to Dr Reddy Laboratories prior to joining IPA as an Advisor. A graduate from Indian…
‘Helps decide on right of monopoly to innovation’
Priyanka Gupta is Solution Consultant with the IP & Science business of Thomson Reuters. She provides intellectual property…
The price of innovation: Which way pharma?
Are the high prices set by pharmaceutical companies for their products justifiable, asks Adefemi Adenuga, GlobalData's analyst…
’Collaborative commercialisation of incremental innovation could help bring affordable new…
Tapan Ray, Director General, OPPI